| Fallopian Tube Carcinoma

Zejula vs Zirabev

Side-by-side clinical, coverage, and cost comparison for fallopian tube carcinoma.

Deep comparison between: Zejula vs Zirabev with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZirabev has a higher rate of injection site reactions vs Zejula based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zirabev but not Zejula, including UnitedHealthcare

Category

Zejula

Zirabev

At A Glance

RouteOral

FrequencyDaily

ClassPARP inhibitor

RouteIV infusion

FrequencyEvery 2-3 weeks

ClassVEGF inhibitor

Indications

Carcinoma, Ovarian Epithelial
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Metastasis from malignant neoplasm of colon and/or rectum
Non-Small Cell Lung Carcinoma
Glioblastoma
Renal Cell Carcinoma
Cervix carcinoma
Malignant neoplasm of ovary
Fallopian Tube Carcinoma
Primary Peritoneal Cancer

Dosing

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line maintenance, HRD-positive) 200 mg orally once daily for patients weighing <77 kg or with platelet count <150,000/mcL; 300 mg orally once daily for patients weighing >=77 kg AND with platelet count >=150,000/mcL; start no later than 12 weeks after most recent platinum-containing regimen.

Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent, germline BRCA-mutated) 300 mg orally once daily; start no later than 8 weeks after most recent platinum-containing regimen.

Metastasis from malignant neoplasm of colon and/or rectum 5 mg/kg IV every 2 weeks with bolus-IFL; 10 mg/kg IV every 2 weeks with FOLFOX4; 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy after progression on a first-line bevacizumab product-containing regimen.

Non-Small Cell Lung Carcinoma 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma 10 mg/kg IV every 2 weeks.

Renal Cell Carcinoma 10 mg/kg IV every 2 weeks in combination with interferon alfa.

Cervix carcinoma 15 mg/kg IV every 3 weeks in combination with paclitaxel and cisplatin or paclitaxel and topotecan.

Malignant neoplasm of ovary, Fallopian Tube Carcinoma, Primary Peritoneal Cancer Stage III/IV following initial surgical resection: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by 15 mg/kg every 3 weeks as a single agent for up to 22 cycles. Platinum-resistant recurrent: 10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg IV every 3 weeks with topotecan (every 3 weeks). Platinum-sensitive recurrent: 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel or carboplatin and gemcitabine for 6-10 cycles, followed by 15 mg/kg every 3 weeks as a single agent.

Contraindications

—

Drug Interactions

845View drug interactions

232View drug interactions

Adverse Reactions

Most common (>10%) Nausea, thrombocytopenia, anemia, fatigue, constipation, musculoskeletal pain, abdominal pain, vomiting, neutropenia, decreased appetite, leukopenia, insomnia, headache, dyspnea, rash, diarrhea, hypertension, cough, dizziness, acute kidney injury, urinary tract infection, hypomagnesemia

Serious Thrombocytopenia, anemia, MDS/AML, bone marrow suppression, hypertension, posterior reversible encephalopathy syndrome, cardiac arrest, intestinal perforation

Postmarketing Pancytopenia, hypersensitivity (including anaphylaxis), posterior reversible encephalopathy syndrome, confusional state, hallucination, cognitive impairment, non-infectious pneumonitis, photosensitivity, hypertensive crisis

Most common (>10%) Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, exfoliative dermatitis.

Serious Gastrointestinal perforations and fistulae, surgery and wound healing complications, hemorrhage, arterial thromboembolic events, venous thromboembolic events, hypertension, posterior reversible encephalopathy syndrome, renal injury and proteinuria, infusion-related reactions, ovarian failure, congestive heart failure.

Postmarketing Polyserositis, pulmonary hypertension, mesenteric venous occlusion, gastrointestinal ulcer, intestinal necrosis, anastomotic ulceration, pancytopenia, gallbladder perforation, osteonecrosis of the jaw, renal thrombotic microangiopathy, nasal septum perforation, arterial aneurysms/dissections/rupture.

Pharmacology

Niraparib is an inhibitor of PARP enzymes (PARP-1 and PARP-2) that play a role in DNA repair; inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes results in DNA damage, apoptosis, and cell death in tumor cell lines with or without BRCA1/2 deficiencies.

Bevacizumab-bvzr binds VEGF and prevents its interaction with receptors Flt-1 and KDR on the surface of endothelial cells, inhibiting endothelial cell proliferation, new blood vessel formation, and metastatic disease progression.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Zejula